Continuous administration of Il-13 to mice induces extramedullary hemopoiesis and monocytosis.
IL-13, a recently identified Th2 cytokine, shares some, but not all, IL-4 functions, including inhibition of monocyte and macrophage activation, stimulation of human B cells, and induction of growth and differentiation of mouse bone marrow cells in vitro. We have now tested the in vivo effects of recombinant mouse IL-13 (rIL-13) from stably transfected, high expressing BW5147 thymoma cells. After purification by anion exchange chromatography, rIL-13 was administered in the peritoneal cavity of BALB/c mice via osmotic pump for 7 days. Spleens from the rIL-13-treated mice were significantly enlarged compared with control spleens due to increased cellularity. In particular, increased numbers of immature erythroblasts and megakaryocytes were observed in splenic sections after rIL-13 treatment. Spleen cells from rIL-13-treated mice showed greatly increased responsiveness in vitro to recombinant forms of mouse IL-3, mouse granulocyte-macrophage CSF, or human CSF-1 and, to a lesser extent, to mouse IL-4 or IL-13. Moreover, the rIL-13-treated mice also showed significant increases in CFU-E, CFU-C, and erythroid burst colonies in the spleen, further indicating the presence of increased numbers of hemopoietic precursors. Hematologic analyses indicated that rIL-13 treatment induced slight anemia and striking monocytosis. Finally, spleen cells from rIL-13-treated mice produced significantly more IL-6 upon LPS stimulation. Interestingly, the strong Th2 response induced by Nippostrongylus brasiliensis infection was also accompanied by an increase in hemopoietic precursor frequencies in the spleen. Collectively, these data indicate that exogenous rIL-13 induces extramedullary hemopoiesis in mice and suggest that endogenous IL-13 may contribute to replenishment of effector cells during strong Th2 responses.
Lai
Y H
YH
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.
Heslan
J M
JM
Poppema
S
S
Elliott
J F
JF
Mosmann
T R
TR
D000740:Anemia / Q000139:chemically induced; D000818:Animals; D001483:Base Sequence; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D016207:Cytokines / Q000494:pharmacology; D004334:Drug Administration Schedule; D005260:Female; D006411:Hematopoiesis, Extramedullary / Q000187:drug effects / Q000276:immunology*; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D007260:Infusion Pumps; D007263:Infusions, Parenteral; D018793:Interleukin-13 / Q000008:administration & dosage* / Q000302:isolation & purification / Q000494:pharmacology; D015850:Interleukin-6 / Q000096:biosynthesis; D007964:Leukocytosis / Q000139:chemically induced / Q000276:immunology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D009000:Monocytes / Q000187:drug effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000302:isolation & purification; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013163:Splenomegaly / Q000139:chemically induced; D017206:Strongylida Infections / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology
D016207:Cytokines; D018793:Interleukin-13; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011994:Recombinant Proteins